Modular Medical, Inc. (MODD) Stock Price & Analysis
Modular Medical, Inc. (MODD) fell 3.91% to USD 4.67 as of June 10, 2026 at 12:04 UTC, according to Nexqual real-time market data.
MODD last closed at USD 4.86; the session ranged USD 4.59–4.88 on volume of 18,713 shares. Market capitalization is $25.27M, with a 52-week range of USD 3.13–30 (NCM). Source: Nexqual, June 10, 2026 at 12:04 UTC.
Key Statistics (as of June 10, 2026 at 12:04 UTC)
| Price | USD 4.67 |
|---|---|
| Change | ▼ 3.91% (down) |
| Previous Close | USD 4.86 |
| Open | USD 4.88 |
| Day Range | USD 4.59 – 4.88 |
| 52-Week Range | USD 3.13 – 30 |
| Volume | 18,713 shares |
| Market Cap | $25.27M |
| Exchange | NCM |
Technical Analysis (MODD)
Nexqual's technical model rates MODD "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 12:04 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.21 (neutral) |
| vs SMA50 | Above (USD 4.54) |
| MACD | 0.11 (positive) |
Analyst Ratings (MODD)
Wall Street analysts rate MODD "None", per Nexqual as of June 10, 2026 at 12:04 UTC.
| Consensus Rating | None |
|---|
Earnings (MODD)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD -3.9 vs est -3.6 ▼ miss |
| 2024-09-30 | USD -4.2 vs est -3.3 ▼ miss |
| 2024-06-30 | USD -3.6 vs est -5.55 ▲ beat |
| 2024-03-31 | USD -4.2 vs est -6 ▲ beat |
Source: Nexqual, June 10, 2026 at 12:04 UTC.
Financials & Fundamentals (MODD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -331.77% |
| Debt / Equity | 8.57 |
| Current Ratio | 1.59 |
| Total Cash | $2.94M |
| Total Debt | $504,000 |
| Free Cash Flow | $-15.67M |
Source: Nexqual, June 10, 2026 at 12:04 UTC.
Financial Health Score (MODD)
Nexqual rates Modular Medical, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$22M |
| Efficiency | Critical — ROE -332%, ROA -149.8% |
Ownership (MODD)
| Insider Ownership | +2.55% |
|---|---|
| Institutional Ownership | +31.23% |
| Shares Outstanding | 5.41M |
| Float | 2.22M |
| Short % of Float | +2.17% |
Source: Nexqual, June 10, 2026 at 12:04 UTC.
Leadership (MODD)
Modular Medical, Inc. is led by James E. Besser (age 49), Chief Executive Officer, per Nexqual as of June 10, 2026 at 12:04 UTC.
| Chief Executive Officer | James E. Besser (age 49) |
|---|---|
| Founder, Chairman, President, CFO & Treasurer | Paul M. DiPerna (age 66) |
| Chief Operating Officer | Kevin Schmid (age 66) |
Major Backers & Investors (MODD)
Notable institutional backers of Modular Medical, Inc. include AWM Investment Company, Inc., Solas Capital Management, LLC, Bleichroeder LP, according to Nexqual as of June 10, 2026 at 12:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AWM Investment Company, Inc. | 6.78% |
| Solas Capital Management, LLC | 5.32% |
| Bleichroeder LP | 3.46% |
| 683 Capital Management LLC | 2.31% |
| Bard Associates Inc. | 1.84% |
| Heights Capital Management, Inc | 0.92% |
| Sio Capital Management, LLC | 0.48% |
| Fidelity | 0.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.06% |
| Geode Capital | 0.51% |
Source: Nexqual, June 10, 2026 at 12:04 UTC.
From Modular Medical, Inc.'s Latest SEC 10-K Filing (filed 2025-06-20)
Key Strengths & Strategy (as disclosed to the SEC)
- By October 31, 2025, we plan to submit a 510(k) premarket notification to the FDA for a new and improved version of the MODD1, the Pivot, which will use our proprietary, integrated insulin-delivery set manufactured by us.
- We believe this represents a total addressable market of approximately $3 billion for us, assuming cartridge revenue of approximately $4,100 per patient, per year.   We are dedicated to helping all people with diabetes gain access to high quality care.
- The patents and patent applications cover various aspects of our technology, including our proprietary fluid movement technology and associated features of our insulin delivery methodology.
- Class I devices are those for which reasonable assurance of safety and effectiveness can be maintained through adherence to general controls which include compliance with the applicable portions of the FDA's Quality System Regulation (the "QSR"), as well as regulations requiring facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials.
Partnerships
- The MODD1 was designed from the beginning for mass manufacturing, and we have partnered with a tier-one medical device manufacturer, Phillips Medisize, to establish processes and "lights out" or near lights out production assembly lines whereby a minimal number of workers will be required in the production facility.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.23 | ▼ 1.52% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| SVRE | SaverOne 2014 Ltd. | USD 3.95 | ▲ 5.2% |
| AIMD | Ainos, Inc. | USD 2.04 | ▲ 4.62% |
| BJDX | Bluejay Diagnostics, Inc. | USD 4.5 | ▼ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:04 UTC. This page is informational and not investment advice.